4/A: Processa Pharmaceuticals Director Amends Filing to Reflect Warrant Transactions

Sentiment:

SEC Filing (Form 4/A)


Justin W. Yorke, a director of Processa Pharmaceuticals, filed an amendment to a previous Form 4, detailing warrant acquisitions and holdings through indirect ownership.

Summary

  • Justin W. Yorke, a director of Processa Pharmaceuticals, filed an amended Form 4 with the SEC.
  • The amendment, dated February 18, 2025, revises a previous filing from January 29, 2025.
  • The filing details transactions involving common stock and warrants.
  • Yorke directly disposed of 3,737 shares of common stock.
  • Yorke indirectly holds 12,400 shares of common stock through a Directed Trust Company FBO Justin Yorke IRA.
  • He also indirectly holds 31,232 shares through Richland Fund, LLC.
  • Yorke acquired 12,400 warrants with an exercise price of $0.65, expiring on January 29, 2030, through a Directed Trust Company FBO Justin Yorke IRA.
  • He also acquired 6,200 warrants with the same terms through the same IRA.
  • Following the reported transactions, Yorke indirectly holds 12,400 and 6,200 warrants through the Directed Trust Company FBO Justin Yorke IRA.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing transactions by a company insider; it doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

  • Shareholders are informed about insider transactions, promoting transparency.

Key Dates

DateDescription
01/27/2025Date of earliest transaction
01/29/2025Date of original filing and warrant acquisition
01/29/2030Expiration date of warrants
02/18/2025Date of amendment filing

Keywords

Form 4, Amendment, Warrants, Common Stock, Processa Pharmaceuticals, Director, Yorke, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.